Protagonist Therapeutics Management
Management criteria checks 3/4
Protagonist Therapeutics' CEO is Dinesh Patel, appointed in Dec 2008, has a tenure of 15.42 years. total yearly compensation is $7.07M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.77% of the company’s shares, worth $11.85M. The average tenure of the management team and the board of directors is 3.3 years and 9.3 years respectively.
Key information
Dinesh Patel
Chief executive officer
US$7.1m
Total compensation
| CEO salary percentage | 9.3% |
| CEO tenure | 15.4yrs |
| CEO ownership | 0.8% |
| Management average tenure | 3.3yrs |
| Board average tenure | 9.3yrs |
Recent management updates
Recent updates
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13
Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04How Many Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Did Insiders Buy, In The Last Year?
Feb 09We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn
Dec 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$7m | US$655k | -US$79m |
| Sep 30 2023 | n/a | n/a | -US$140m |
| Jun 30 2023 | n/a | n/a | -US$138m |
| Mar 31 2023 | n/a | n/a | -US$140m |
| Dec 31 2022 | US$6m | US$630k | -US$127m |
| Sep 30 2022 | n/a | n/a | -US$130m |
| Jun 30 2022 | n/a | n/a | -US$133m |
| Mar 31 2022 | n/a | n/a | -US$122m |
| Dec 31 2021 | US$6m | US$600k | -US$126m |
| Sep 30 2021 | n/a | n/a | -US$108m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$70m |
| Dec 31 2020 | US$2m | US$565k | -US$66m |
| Sep 30 2020 | n/a | n/a | -US$65m |
| Jun 30 2020 | n/a | n/a | -US$73m |
| Mar 31 2020 | n/a | n/a | -US$83m |
| Dec 31 2019 | US$2m | US$545k | -US$77m |
| Sep 30 2019 | n/a | n/a | -US$74m |
| Jun 30 2019 | n/a | n/a | -US$66m |
| Mar 31 2019 | n/a | n/a | -US$45m |
| Dec 31 2018 | US$4m | US$520k | -US$39m |
| Sep 30 2018 | n/a | n/a | -US$28m |
| Jun 30 2018 | n/a | n/a | -US$24m |
| Mar 31 2018 | n/a | n/a | -US$31m |
| Dec 31 2017 | US$790k | US$475k | -US$37m |
Compensation vs Market: Dinesh's total compensation ($USD7.07M) is about average for companies of similar size in the US market ($USD5.66M).
Compensation vs Earnings: Dinesh's compensation has increased whilst the company is unprofitable.
CEO
Dinesh Patel (66 yo)
15.4yrs
Tenure
US$7,067,572
Compensation
Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He served as Interim Chief Financ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 15.4yrs | US$7.07m | 0.77% $ 11.9m | |
| Executive VP & Chief Financial Officer | 2.1yrs | US$1.40m | 0.0038% $ 57.5k | |
| Chief Development Officer | 5.3yrs | US$2.22m | 0.25% $ 3.8m | |
| Founder & VP Technology | 3.3yrs | no data | no data | |
| Executive VP & Chief Technical Officer | 3.3yrs | no data | no data | |
| Executive VP & General Counsel | 3.7yrs | no data | no data | |
| Head of HR & Senior VP of Human Resources | 3.3yrs | no data | no data | |
| Executive VP & Chief Drug Discovery and Preclinical Development Officer | 3.3yrs | no data | no data | |
| Executive Vice President of Business Development | 3.1yrs | no data | no data | |
| Executive Vice President of Portfolio & Program Management | 3.3yrs | no data | no data | |
| Chief Medical Officer | 1.5yrs | no data | 0.0070% $ 106.5k | |
| Interim Head of Regulatory Affairs & Advisor | no data | no data | no data |
3.3yrs
Average Tenure
58.5yo
Average Age
Experienced Management: PTGX's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 15.4yrs | US$7.07m | 0.77% $ 11.9m | |
| Clinical Advisor | 9.3yrs | no data | no data | |
| Independent Director | 6.9yrs | US$351.52k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 9.3yrs | US$188.07k | no data | |
| Independent Chairman | 15.3yrs | US$395.27k | 0.048% $ 730.4k | |
| Independent Director | 7.8yrs | US$364.02k | 0.020% $ 313.0k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Clinical Advisor | no data | no data | no data | |
| Clinical Advisor | no data | no data | no data | |
| Clinical Advisor | no data | no data | no data | |
| Independent Director | 6yrs | US$356.52k | 0.031% $ 469.6k |
9.3yrs
Average Tenure
66yo
Average Age
Experienced Board: PTGX's board of directors are considered experienced (9.3 years average tenure).